These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31831177)

  • 1. Construction of a circularly connected VHH bispecific antibody (cyclobody) for the desirable positioning of antigen-binding sites.
    Hemmi S; Asano R; Kimura K; Umetsu M; Nakanishi T; Kumagai I; Makabe K
    Biochem Biophys Res Commun; 2020 Feb; 523(1):72-77. PubMed ID: 31831177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of camelid VHH bispecific constructs via in-cell intein-mediated protein trans-splicing.
    Shibuya Y; Haga N; Asano R; Nakazawa H; Hattori T; Takeda D; Sugiyama A; Kurotani R; Kumagai I; Umetsu M; Makabe K
    Protein Eng Des Sel; 2017 Jan; 30(1):15-21. PubMed ID: 27881685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically generated IgG2 bispecific antibodies through disulfide bridging.
    Patterson JT; Gros E; Zhou H; Atassi G; Kerwin L; Carmody L; Zhu T; Jones B; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3647-3652. PubMed ID: 28720505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel brick for bispecific antibody construction.
    He Y; Ma H; Wang C; Ai Z; Wu Q; Chen H; Lu D
    Proteins; 2023 Aug; 91(8):1065-1076. PubMed ID: 36964928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
    Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
    Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
    Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
    Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
    Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single homogeneous assay for simultaneous measurement of bispecific antibody target binding.
    Christian EA; Hussmann GP; Babu M; Prophet M; Mazor Y; Chen W; Grigoriadou C; Lin S
    J Immunol Methods; 2021 Sep; 496():113099. PubMed ID: 34224737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics.
    Li H; Er Saw P; Song E
    Cell Mol Immunol; 2020 May; 17(5):451-461. PubMed ID: 32313210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions.
    Mullin M; McClory J; Haynes W; Grace J; Robertson N; van Heeke G
    MAbs; 2024; 16(1):2341443. PubMed ID: 38666503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
    Li Y; Zhou C; Li J; Liu J; Lin L; Li L; Cao D; Li Q; Wang Z
    PLoS One; 2018; 13(1):e0191024. PubMed ID: 29357376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.
    Gong S; Ren F; Wu D; Wu X; Wu C
    MAbs; 2017 Oct; 9(7):1118-1128. PubMed ID: 28692328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Di-diabody: a novel tetravalent bispecific antibody molecule by design.
    Lu D; Jimenez X; Zhang H; Atkins A; Brennan L; Balderes P; Bohlen P; Witte L; Zhu Z
    J Immunol Methods; 2003 Aug; 279(1-2):219-32. PubMed ID: 12969563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.